Apellis Committee Says It Plans To Seek Re-examination Following Negative CHMP Opinion For Pegcetacoplan For Geographic Atrophy In The EU
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals announced that it plans to seek re-examination following a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its drug Pegcetacoplan for the treatment of geographic atrophy in the EU.
June 28, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals plans to seek re-examination following a negative CHMP opinion on Pegcetacoplan for geographic atrophy in the EU.
The negative opinion from the CHMP is a significant regulatory setback for Apellis Pharmaceuticals, potentially delaying the approval and market entry of Pegcetacoplan in the EU. This could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100